When Mohs does not clear it: what happens after the fourth stage

Everything written for patients about Mohs surgery leads with the cure rate, and the cure rate is genuinely excellent, as the American Academy of Dermatology's overview of basal cell carcinoma treatment reflects. What that framing does, without meaning to, is set up a mental model in which the day has one shape: you arrive, a layer comes off, it is examined, and either you are done or one more layer comes off and then you are done. For the large majority of people that is exactly what happens.

For a minority it is not, and those are the patients with no map at all. Sitting in a waiting room after a third stage, with a dressing on your face and no clear sense of whether this ends today, is a specific kind of difficult, and it is made considerably worse by having no idea what the possible endings are.

The original element in this piece is a stage-by-stage map. Below is what you are told and when across a long Mohs day, the question worth asking at each escalation point, and the four ways a case can actually end. It is written for the patient who is already in the chair, or who wants to know the shape of the day before they sit in it.

The mechanism first, because it explains everything else. Mohs removes a thin layer, maps it, and examines the entire outer surface under a microscope while you wait. If tumor cells appear at the edge, the surgeon knows precisely where on the map they are and removes another layer from that specific area only. Each cycle is a stage. The reason the technique achieves high clearance is that it inspects effectively the whole margin rather than sampling slices of it, and the reason it takes all day is that the tissue processing between stages is real laboratory work.

So a case that runs to four or five stages is not a case that is going badly in the sense of something being done wrong. It is a case where the tumor is bigger or more irregular than it looked on the surface, and the technique is doing exactly what it is designed to do. That distinction is worth holding onto, because it is not how it feels at three in the afternoon.

Stage one. You are told the layer is out and given a rough waiting time, usually somewhere around an hour. Almost every case starts here and a majority end here. Nothing to ask yet.

Stage two. Told that tumor was found at one or more edges, shown roughly where on the map, and taken back for another layer. This is entirely routine and it is worth knowing that a substantial share of ordinary cases need it. The question worth asking here is simple and sets up the rest of the day: how big does this look now compared with what you expected. The answer tells you whether you are in a slightly larger version of a normal case or something different.

Stage three. This is the first genuine information point. Most cases have finished by now, so if you are still going, the tumor has meaningful subclinical extension. The question to ask: is this spreading in a direction you expected, and is it still behaving like the tumor type on the biopsy report. That second half matters, because a tumor that looks more aggressive under the microscope than the original biopsy report suggested changes the plan.

Stage four and beyond. Now the conversation should change, and if it does not, you should change it. Three questions belong here. Is there any suggestion of perineural involvement, meaning tumor tracking along a nerve, which is the single most important finding that alters what happens next. Is the reconstruction I was expecting still the reconstruction we are doing. And is it realistic that this finishes today, because that answer determines whether you should be arranging a ride, food, and a change of plans.

The four endings. Every Mohs case ends in one of these, and knowing the list removes most of the fear of the unknown.

Ending one, clear with the planned repair. The overwhelmingly common outcome. Margins are clear, the defect is closed the way it was intended, and reconstruction happens the same day.

Ending two, clear with a bigger repair than planned. Also common in longer cases. The tumor was larger than it appeared, so the resulting defect is larger, and the closure escalates from a simple line to a flap or a graft. Sometimes the repair is deliberately delayed by a day or handed to a reconstructive specialist, particularly around the eyelid, the nose, or the lip. This is not a complication. It is a bigger hole needing a better solution, and taking a day to plan it is often the right call rather than a worrying one.

Ending three, clear but with a feature that means the treatment is not finished. This is the one nobody warns patients about. The margins are clear and the tumor is out, and yet the recommendation is additional treatment, most often radiation. The usual trigger is perineural invasion, or a large and aggressive tumor, or a recurrent one. The published literature on localized non-melanoma skin cancer examines the risk factors for post-surgical relapse and the role of postoperative radiotherapy in exactly this situation (Curr Treat Options Oncol, 2020). Hearing we got it all and then you will need radiation in the same conversation is disorienting, and it makes complete sense once you know that clear margins and low relapse risk are two different questions. Whether radiation is being used as a follow-up to surgery or as an alternative to it is worth clarifying explicitly, since radiation as a primary treatment is a different decision.

Ending four, paused and referred. The least common and the one that generates the most anxiety. The tumor extends deeper or wider than can be safely cleared in an outpatient dermatologic surgery setting, into bone, into the orbit, into major nerve or cartilage structures. The stages stop, the wound is dressed, and the case moves to a multidisciplinary team, which may involve head and neck surgery, oculoplastic surgery, radiation oncology, and medical oncology. The National Cancer Institute maintains a patient-level summary of how skin cancer treatment is organized across those settings (NCI). This is not a failure of the operation. It is the operation identifying, accurately and early, that the problem is larger than the tool.

The four things to have ready if you might be a long case. Certain features predict a longer day: a recurrent tumor, a large one, an aggressive subtype on the biopsy, an ill-defined border you could not see clearly yourself, or a location on the nose, eyelid, ear, or lip. If any apply, arrange a ride regardless of what you have been told about driving yourself, bring food and a phone charger, bring someone who can listen to the afternoon conversation because you will not retain it, and clear the following day. None of that predicts a bad outcome. It removes the logistics from a day where you should be thinking about something else.

What the studies do not tell you. The gap here is specific and it is a real one. Published series report cure rates and average stage counts, which is useful in aggregate and useless for you at two in the afternoon. What almost nobody publishes is the distribution: what proportion of cases run to four stages, to five, to six, and what happens to those cases. So there is no honest number to give you for the likelihood of your case being the long one, and anyone who gives you a precise figure is estimating. There is also very little research on the patient experience of a long Mohs day itself, on what people were told, when, and what they wished they had been told, which is why an article like this has to be assembled from clinical structure rather than cited from a study of it.

The thing to take away. A fourth stage is not a sign that something has gone wrong. It is a sign that the technique is finding tumor you could not see, which is the entire reason it was chosen over a wider single excision. The risk on a long day is not the surgery. It is being too rattled to ask the three questions at stage four, which are the questions that tell you which of the four endings you are heading toward. Knowing what to expect on the day covers the ordinary version. This is the map for the other one.